title: Dose-ranging study of a single injection of pneumococcal conjugate vaccine (1 ×, 2 ×, or 4 ×) in healthy subjects aged 70 years or older.
abstract: Healthy adults aged ≥ 70 years (N=443) with no history of pneumococcal vaccination received 7- or 9-valent pneumococcal conjugate vaccine (PCV7 or PCV9) at 1 × (PCV7 only), 2 × (PCV7+PCV9), or 4 × (2 × PCV7+2 × PCV9) dosage in a randomised, open-label study evaluating pneumococcal protein conjugate vaccine (PnC). Controls received 23-valent pneumococcal polysaccharide vaccine (PPV). Both geometric mean concentration enzyme-linked immunosorbent assay and opsonophagocytic activity antibody titres assessed 1 month after vaccination were significantly increased over baseline titres for all PCV7 serotypes, with a trend toward a dose-dependent immune response. Local reactions for the 4 × dose, but not the 2 × dose, were statistically significantly higher than for the 1 × dose. No treatment-related serious adverse events occurred.
authors: Research Centre for Medical Studies, Institute of Clinical Pharmacology, Charité Universitätsmedizin Berlin, Hohenzollerndamm 2, Berlin, Germany. haloheck@zedat.fu-berlin.de
authors: H
authors: H
authors: Lode
authors: B
authors: B
authors: Schmoele-Thoma
authors: W
authors: W
authors: Gruber
authors: N
authors: N
authors: Ahlers
authors: P
authors: P
authors: Fernsten
authors: S
authors: S
authors: Baker
authors: A
authors: A
authors: Razmpour
authors: G
authors: G
authors: Siber
authors: J
authors: J
authors: Hackell
authors: S
authors: S
authors: Lockhart
authors: O
authors: O
authors: Burkhardt
authors: T
authors: T
authors: Welte
authors: A
authors: A
authors: de Roux